Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma-Reference-Cited by-同舟云学术

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma

Published:2018-04-19 Issue:6 Volume:7 Page:2256-2268
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Lund Johan¹^ORCID,Gruber Astrid¹,Lauri Birgitta²,Duru Adil Doganay¹³,Blimark Cecilie⁴,Swedin Agneta⁵,Hansson Markus⁵,Forsberg Karin⁶,Ahlberg Lucia⁷,Carlsson Conny⁸,Waage Anders⁹,Gimsing Peter¹⁰,Vangsted Annette Juul¹⁰¹¹,Frølund Ulf¹¹,Holmberg Erik¹²,Gahrton Gösta¹,Alici Evren¹,Hardling Mats¹³,Mellqvist Ulf-Henrik⁴,Nahi Hareth¹

Affiliation:

1. Department of Hematology; Karolinska University Hospital; Stockholm Sweden

2. Department of Internal Medicine; Sunderby Hospital; Luleå Sweden

3. Nova Southeastern University (NSU); Fort Lauderdale Florida

4. Department of Hematology; Sahlgrenska University Hospital; Gothenburg Sweden

5. Department of Hematology; Skåne University Hospital; Lund Sweden

6. Department of Hematology; Norrland University Hospital; Umeå Sweden

7. Department of Hematology; University Hospital of Linköping; Linköping Sweden

8. Department of Internal Medicine; Hallands Hospital; Halmstad Sweden

9. Department of Cancer Research and Molecular Medicine; Norwegian University of Science and Technology; Trondheim Norway

10. Department of Hematology; Rigshospitalet; Copenhagen Denmark

11. Department of Hematology; Zealand University; Roskilde Denmark

12. Department of Oncology; Institute of Clinical Sciences; Gothenburg Sweden

13. Department of Hematology; Uddevalla Hospital; Uddevalla Sweden

Funder

Celgene

Cancerfonden

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Reference24 articles.

1. Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population;Liwing;Br. J. Haematol.,2014

2. Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma - a retrospective population based study of 1162 patients;Lund;Eur. J. Haematol.,2014

3. Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation;McCormack;Drugs Aging,2015

4. An update on the use of lenalidomide for the treatment of multiple myeloma;Zagouri;Expert Opin. Pharmacother.,2015

5. Celgene Corporation REVLIMID prescribing information 2015 http://www.revlimid.com/wp-content/uploads/full-prescribing-information.pdf

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenalidomide use in multiple myeloma (Review);Molecular and Clinical Oncology;2023-11-28